Investigating the effects of the hormone kisspeptin on human brain activity

Not Applicable

Completed

• Conditions: Investigation of brain processing in Hypoactive Sexual Desire Disorder; Mental and Behavioural Disorders; Hypoactive Sexual Desire Disorder

• Registration Number: ISRCTN17271094
• Lead Sponsor: Imperial College London

Brief Summary

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36287566/ (added 27/10/2022) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36735255/ (added 06/02/2023)

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-29
• Study Completion: 2022-12-01
• Last Update Posted: 2023-02-20

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1. Aged 18 – 70 years (men)
2. Aged >18 years and pre-menopausal (women)
3. Right handed
4. Non-smoker
5. Heterosexual orientation
6. Low sexual desire, meeting the DSM-5 criteria for Hypoactive Sexual Desire Disorder
7. Free of current or past physical or psychiatric illness
8. Naive to psychoactive substances, prescribed or illicit, for a minimum of 6 months prior to screening.
9. Normal or corrected-to-normal vision.
10. Absence of a history of sexual aggression/abuse/phobia or psychotherapy/counselling

Exclusion Criteria

1. History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or potentially cause harm to the participant
2. Medical or psychological conditions that would impair their ability to participate reliably in the study or give informed consent
3. Pregnancy and/or breastfeeding
4. Post-menopausal (female)
5. Any implanted material in the body that would preclude magnetic resonance imaging (MRI) for safety reasons
6. Inability to tolerate MRI scanning
7. Without access at home to a telephone, or other factor likely to interfere with ability to participate reliably in the study
8. History of hypersensitivity to any of the components administered
9. Treatment with an investigational drug within the preceding two months
10. Those who have or intend to donate blood or blood products within three months before or following study completion
11. A history of major haematological, renal, thyroid or hepatic abnormalities or significant cardiovascular disease
12. A history of cancer

Study & Design

• Study Type: Interventional
• Study Design: Not specified